New Drug's breast milk safety under microscope

NCT ID NCT06961747

Recruiting now Knowledge-focused Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing how much of the drug zilucoplan gets into breast milk after daily injections. Fifteen healthy lactating women who have already decided to stop breastfeeding will provide milk samples over 24 hours. The goal is to estimate how much drug an infant might consume, helping to assess safety for future use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zilucoplan
What this could lead to: If successful, this study will help determine whether zilucoplan is safe for infants exposed through breast milk, guiding future use in breastfeeding mothers.
What could go wrong: This is a very small, early-phase study in healthy women, not patients. Results may not reflect real-world conditions or guarantee safety for all infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

UP0137 1
RECRUITING

Salt Lake City, Utah, 84124, United States
UP0137 2
RECRUITING

San Antonio, Texas, 78209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.